In addition, a preliminary observational analysis on a large number of cystinotic patients has shown an improved renal outcome in patients treated with the anti-inflammatory drug indomethacin that (Emma et al., 2016), incidentally, has been demonstrated to inhibit the NF-κB activity (Sung et al., 2004), therefore supporting a pathogenic role of inflammation in the progression of renal disease. Here, NFKB1 is linked to kidney disorder.